 |
 |
E-MOVE reports from the 14th International Congress on Parkinson's Disease, Helsinki July 28-Aug 1. Poster and Platform session numbers refer to those in the abstract book, published in Parkinsonism and Related Disorders 2001;7(Supplement). High-dose therapy with pergolide--results of a prospective randomized trial J Schwarz, G Arnold, T Gasser, HP Hundemer S-SA-002 Thirty-three patients (mean Hoehn and Yahr stage 2.5) on levodopa and dopamine agonist therapy received increasing doses of pergolide with simultaneous reduction of other agonists and levodopa. Baseline doses were 2.5 mg pergolide and 500 mg levodopa. At 24 weeks, doses were 7.8 mg pergolide and 258 mg levodopa. Twenty-seven patients completed the trial; 2 patients dropped out for lack of efficacy, and 1 patient required hospitalization for psychosis. Motor symptoms on UPDRS part III improved from 26 at baseline to 22 at 24 weeks (p=0.01), with specific effect on tremor. Neither dyskinesias nor activities of daily living were significantly affected. Adverse events included anxiety, hallucinations, weakness, abdominal pain, and edema. Dr. Schwarz noted that many patients have remained on high-dose pergolide for several years, although 2 developed ergotism requiring a reduction in dose. Other E-MOVE reports on pergolide for PD are archived at http://www.wemove.org/emove/article.asp?ID=223 http://www.wemove.org/emove/article.asp?ID=119 Supported by Eli Lilly --- Funding for E-MOVE meeting reports is provided in part by unrestricted educational grants from Allergan Inc., Elan Pharmaceuticals, and Pharmacia Corporation. Copyright 2000 WE MOVE Editor: Richard Robinson ([log in to unmask]) This service is provided free of charge to the Internet community, courtesy of WEMOVE.org. This document may be freely redistributed by email only in its unedited form. We encourage you to share it with your colleagues. E-MOVE archives, plus information on subscribing, are available at http://www.wemove.org/emove. To unsubscribe, send an e-mail to [log in to unmask], with "unsubscribe e-move" in the message body. E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for Movement Disorders) 204 West 84th Street New York, NY 10024 TEL 800-437-MOV2 TEL 212-875-8312 FAX 212-875-8389 http://www.wemove.org ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn